OncoMatch/Clinical Trials/NCT07234487
Comparison of AVD + Low-Dose Nivolumab vs. PET-Adapted BEACOPP-like in Advanced cHL
Is NCT07234487 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Nivo-AVD and BEACOPP-like for hodgkin lymphoma.
Treatment: Nivo-AVD · BEACOPP-like — Patients in this prospective multicenter phase II study will be randomized between two first-line therapy strategies for advanced stages of cHL. In the Nivo-AVD cohort, patients will receive 2 cycles of nivolumab monotherapy followed by a switch to Nivo-AVD combination therapy (total of 6 cycles); in the Standard cohort, patients will receive therapy according to current clinical guidelines in Russian Federation for first-line therapy of cHL, which include starting first-line therapy with 2 cycles of BEACOPP-like regimens and, after assessing response after 2 courses, switching to A(B)VD or continuing with BEACOPP-like regimens
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Hodgkin Lymphoma
Disease stage
Required: Stage IIB, III, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Lab requirements
Kidney function
creatinine > 2 norms
Liver function
alanine aminotransferase, aspartate aminotransferase > 5 norms; bilirubin > 1.5 norms
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07234487 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage IIB or III or IV is required.
Is there an age limit?
Yes. Patients must be 60 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages